SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Aug 22, 2019
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Aug. 22, 2019 · CIK: 0001137883 · Accession: 0000000000-19-012750
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233349
Letter
August 22, 2019 Chaim Lebovits President and Chief Executive Officer Brainstorm Cell Therapeutics Inc. 1325 Avenue of Americas, 28th Floor New York, NY 10019 Re:Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-3 Filed August 16, 2019 File No. 333-233349 Dear Mr. Lebovits: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Thomas B. Rosedale, Esq. - BRL Law Group LLC
Show Raw Text
August 22, 2019
Chaim Lebovits
President and Chief Executive Officer
Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas, 28th Floor
New York, NY 10019
Re:Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-3
Filed August 16, 2019
File No. 333-233349
Dear Mr. Lebovits:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Thomas B. Rosedale, Esq. - BRL Law Group LLC